Survival in peritoneal carcinomatosis has moved from being measured in months to being measured in years. Two decades ago the median was 6-12 months and the disease was considered terminal. Today, with complete cytoreductive surgery and HIPEC in selected patients, the median stands at 40-60 months, and long-term cures are documented in pseudomyxoma peritonei. The heaviest factor is complete cytoreduction (CC-0): patients who finish surgery with no visible residual tumour reach a median of 40-60 months, against 12-20 months when disease larger than 2.5 mm remains. The specific figures vary widely by tumour of origin.
How much has survival in peritoneal carcinomatosis improved?
The change is an order of magnitude. In the 1990s peritoneal carcinomatosis was regarded as disseminated, terminal disease, with median survival of 6-12 months on systemic chemotherapy alone. Adding complete cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy transformed that picture in suitable tumours: today we speak of medians of 3-5 years in selected patients, and of prolonged survival close to cure in low-grade pseudomyxoma peritonei. The difference does not come from a new drug but from a conceptual shift, treating peritoneal disease as a locoregional problem amenable to surgery rather than as distant metastasis that is inoperable by definition. That shift also shows in perioperative mortality, which has fallen from unacceptable rates in the earliest series to below 3% in centres with consolidated experience. The procedure moved from experimental to standard of care in selected indications.
That shift explains why the prognosis given to a patient can differ so much between centres. A unit that does not perform cytoreduction with HIPEC will assess the case using the figures of the systemic scenario, which are the ones it knows.
What is the single most important prognostic factor?
Complete cytoreduction, known as CC-0: no visible residual tumour at the end of the operation. Patients who achieve CC-0 record median survival of 40-60 months, against 12-20 months when residual disease larger than 2.5 mm remains. No other factor has a comparable effect, and it is also the only one the surgical team can act on directly. The decisive clinical question is therefore not "how long is left" but "can a complete cytoreduction be achieved in this case, and which team can achieve it". Extensive involvement of the small bowel, the hepatic hilum or the retroperitoneum are the findings that most often prevent it. The CC classification is graded in several steps: CC-0 with no visible disease, CC-1 with nodules under 2.5 mm, and CC-2 and CC-3 with progressively larger residue. Only the first two steps are associated with a clear survival benefit.
One nuance matters: CC-0 does not depend on the patient alone. It also depends on technique, on the operating time the team is prepared to commit, and on experience with multivisceral resections. That is why centre volume appears consistently as an independent prognostic variable in published series.
What is the survival for each tumour of origin?
The primary tumour sets differences measured in years. In pseudomyxoma peritonei, 10-year survival is 50-70%, the best of the group. In peritoneal mesothelioma, medians with surgery and HIPEC range from 60 to 92 months. In colorectal origin, 5-year survival is 30-50% with surgery plus HIPEC, against under 5% with systemic chemotherapy alone. In ovarian origin, medians sit at 35-55 months with optimal cytoreduction, and the tumour's chemosensitivity allows a higher PCI to be tolerated. In gastric origin, the poorest of the group, the median is 18-24 months in highly selected cases. They should also be read with the publication date in mind: older series include patients treated with superseded chemotherapy regimens and less refined surgical technique, so current results tend to sit in the upper part of each range. In pseudomyxoma and mesothelioma, moreover, the follow-up needed to report ten-year data means published outcomes reflect practice from more than a decade ago.
These figures come from specialist-centre series with strict selection criteria, not from general populations. Applying them to a patient who does not meet those criteria overstates the expected result, and applying them the other way around understates it. The gastric approach is set out in detail in our article on HIPEC in gastric carcinomatosis.
Does the PCI score predict survival?
Yes, and it is the second most important variable after complete cytoreduction. The Peritoneal Cancer Index divides the abdomen into 13 regions and scores implant size in each one, on a range from 0 to 39. A PCI below 10 is associated with an excellent outlook, 10 to 20 with an intermediate one, and above 20 with clearly poorer survival. The reason is largely mechanical: the higher the PCI, the less likely a CC-0 becomes without resections that would compromise bowel function. It carries one important practical limitation: the definitive PCI is only known during surgery, because CT systematically underestimates implants smaller than 5 mm and mesenteric involvement. Diagnostic laparoscopy is used precisely to narrow that margin of error before committing to major surgery. An imaging-estimated PCI and a surgical PCI can differ by several points.
The threshold is not universal. Higher PCI values are accepted in ovarian cancer because the response to subsequent chemotherapy offsets part of the tumour burden, whereas selection in gastric origin is far more restrictive. The PCI is therefore never read in isolation, but alongside tumour type and surgical feasibility.
Does the treating centre affect survival?
Yes, measurably. Centres performing more than 30 cytoreduction with HIPEC procedures a year consistently achieve better CC-0 rates, lower perioperative mortality and better long-term survival. The volume-outcome relationship is particularly marked in this surgery because the operations are long, frequently involve multivisceral resections, and require complex perioperative management from a trained anaesthesia, intensive care and nutrition team, not just an expert surgeon. Complications that are not prevented or not rescued in time delay subsequent chemotherapy and erode the oncological benefit gained in theatre. The effect is measured above all in failure-to-rescue: not so much in having fewer complications as in detecting and resolving them in time. A centre with a trained team turns into a resolved episode what elsewhere ends in late reoperation, a prolonged intensive care stay and a delay of months before oncological treatment resumes.
This is why choosing the centre and requesting a second opinion are not administrative formalities but decisions with a prognostic weight of their own.
What role does systemic chemotherapy play?
Complementary and necessary, but not a substitute. Neoadjuvant chemotherapy, given before surgery, can reduce tumour burden and convert initially inoperable cases into operable ones, while also acting as a test of tumour biology: progression during treatment usually argues against surgery. Adjuvant chemotherapy, given afterwards, targets residual microscopic disease. The best published results correspond to the full sequence, that is, perioperative chemotherapy plus optimal cytoreduction plus HIPEC, supported by nutritional support and prehabilitation. In colorectal and gastric origin, the usual pathway includes chemotherapy before surgery; in low-grade pseudomyxoma, by contrast, its role is marginal because the tumour responds poorly to cytotoxics and almost the entire therapeutic weight falls on surgery. The sequence is therefore not fixed: it is set by tumour origin, by the response observed and by the patient condition at each point of the process.
The balance between the two is decided in a multidisciplinary board. Bringing surgery forward in a tumour with aggressive biology, or delaying it too long in a controlled one, are the two most common sequencing errors, and both translate into lost survival.
Would you like your case reviewed? At Quenet Torrent Institute we are a European referral centre for the treatment of peritoneal carcinomatosis with cytoreductive surgery and HIPEC. Request a second opinion.
Frequently asked questions
The most common questions answered with concrete data.
Has survival in peritoneal carcinomatosis improved?
Yes, substantially. Two decades ago median survival was 6-12 months. With complete cytoreductive surgery and HIPEC, medians of 3-5 years are now reached in selected patients, and long-term survival close to cure is documented in low-grade pseudomyxoma peritonei.
What is the most important prognostic factor?
Complete cytoreduction (CC-0), meaning no visible residual tumour at the end of surgery. Patients achieving CC-0 record median survival of 40-60 months, against 12-20 months when residual disease larger than 2.5 mm remains.
What survival is achieved in carcinomatosis of colorectal origin?
In selected patients treated with cytoreductive surgery and HIPEC in expert centres, 5-year survival reaches 30-50%, against under 5% with systemic chemotherapy alone.
What is the prognosis of pseudomyxoma peritonei?
Pseudomyxoma peritonei has the most favourable prognosis of all peritoneal carcinomatoses. Survival at 10 years exceeds 50-70%, and results in low-grade histological subtypes approach cure.
What survival is achieved in ovarian origin?
Median survival in ovarian cancer with peritoneal involvement treated with cytoreductive surgery ranges from 35 to 55 months in patients with optimal cytoreduction. The tumour's high chemosensitivity allows higher PCI values to be tolerated than in other origins.
What survival is achieved in gastric origin?
Gastric origin carries the poorest prognosis. In highly selected cases treated in specialist centres, median survival is 18-24 months. Strict selection based on a low PCI and complete cytoreduction is essential.
Does the PCI score predict survival?
Yes. A PCI below 10 is associated with an excellent prognosis, 10 to 20 with an intermediate prognosis, and above 20 with poorer survival. The PCI must be interpreted alongside tumour type and the feasibility of complete cytoreduction.
Does centre volume affect survival?
Yes. Centres performing more than 30 CRS+HIPEC procedures a year consistently achieve better complete cytoreduction rates, lower perioperative mortality and better long-term survival.
What role does systemic chemotherapy play in survival?
Perioperative chemotherapy is part of the overall treatment. Neoadjuvant chemotherapy can reduce tumour burden before surgery and adjuvant chemotherapy targets possible residual microscopic cells. Combining optimal surgery, HIPEC and systemic chemotherapy produces the best results.
What is peritoneal mesothelioma and what survival does it have?
Peritoneal mesothelioma is a rare tumour arising from the mesothelial cells of the peritoneum. Treated with cytoreductive surgery and HIPEC in expert centres, median survival ranges from 60 to 92 months, significantly better than with systemic chemotherapy alone.